Develops rapid, whole genome sequencing-based diagnostic tools that provide same-day identification of pathogens and antimicrobial resistance profiles directly from clinical samples, eliminating the 2-5 day wait for culture-based methods. This technology enables precise, timely treatment decisions for life-threatening infections, reducing reliance on broad-spectrum antibiotics and improving patient outcomes.
Funding
$50.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current culture-based diagnostic methods for identifying pathogens and their antimicrobial resistance profiles can take 2-5 days, delaying appropriate treatment for life-threatening infections. This delay forces physicians to rely on broad-spectrum antibiotics, which can be ineffective and contribute to the rise of antibiotic-resistant organisms. The lack of rapid diagnostics hinders precision medicine approaches in treating severe infections like sepsis.
Solution
Day Zero Diagnostics is developing rapid, whole-genome sequencing-based diagnostic tools that identify pathogens and their antimicrobial resistance profiles directly from clinical samples within hours. This technology enables physicians to make timely and precise treatment decisions, reducing the need for broad-spectrum antibiotics and improving patient outcomes. The company's approach aims to deliver full-spectrum organism identification and antimicrobial resistance/susceptibility profiling, empowering clinicians to practice precision medicine for patients with life-threatening infections. Day Zero Diagnostics also offers a rapid turnaround service, epiXact, which uses whole-genome sequencing to provide infection control professionals with precise information on pathogen relatedness in less than 2 days, facilitating early and confident intervention decisions for healthcare-associated infections.
Target Audience
The primary target audience includes physicians in hospitals treating life-threatening infections, as well as infection control professionals managing healthcare-associated infections.
Features
- Rapid whole-genome sequencing for pathogen identification and antimicrobial resistance profiling
- Direct-from-sample analysis, eliminating the need for culture-based methods
- Same-day results for faster treatment decisions
- epiXact service for rapid HAI (healthcare-associated infections) control using whole-genome sequencing
- Computational diagnostic algorithms for accurate and comprehensive analysis
- Big data analytics for identifying trends and patterns in infectious diseases